Amicus is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales in 2028. The Company anticipates continuing to grow its current commercial ...

Fabry Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth ...

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held ...

AceLink is advancing a small-molecule treatment option for Fabry disease that could provide a more convenient alternative to ...

Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (GLA), which leads to complex multisystemic involvement, with the majority of patients ...

Like we explained, legumes are high in oligosaccharides, so they really have the capacity to trigger some tooting across the ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...

The study showed that the longest treated patient maintained elevated alpha-galactosidase A activity ... all 18 patients who started the study on enzyme replacement therapy (ERT) have been ...

According to research, taking the supplement can help enhance digestion and easy gut problems like bloating, gas and stomach ...

These supplements often contain enzymes such as amylase, lipase, and protease. Some also include lactase and alpha-galactosidase, which the body does not naturally produce, even in healthy ...